newsfilter
← Latest News
Business Wire·

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

Estimated $35.5M - $36.1M in Rubraca® (rucaparib) global sales for Q4 2021 and $148.3M - $148.9M for FY 2021 Continuing impact on ovarian cancer diagnoses and treatments from COVID-19 Q4/FY 2021 Operating Results call planned for February 23,